From microcirculation to cardiac event: protection with Preterax.
Several studies have demonstrated that abnormalities in the function and structure of the coronary microcirculation occur in many clinical conditions, including arterial hypertension in which it might contribute to cardiovascular morbidity and mortality. This dysfunction is caused by remodelling of vascular and extravascular structures as well as abnormal coronary haemodynamics. Whether antihypertensive treatment can lead to reverse remodelling of the coronary microvasculature remains to be determined. The preliminary results of a recent study in patients with arterial hypertension and left ventricular hypertrophy show that 6 months' treatment with a combination of perindopril and indapamide is accompanied by a significant decrease in blood pressure and left ventricular mass and an increase in resting and hyperaemic myocardial blood flow measured non-invasively with positron emission tomography. This suggests that coronary microvascular dysfunction can be reversed by treatment with these drugs and might contribute to the prevention of ischaemic heart disease in these patients.
Camici
Paolo G
PG
Medical Research Council Clinical Sciences Centre and National Heart and Lung institute, Imperial College, London, UK. paolo.camici@csc.mrc.ac.uk
D000959:Antihypertensive Agents / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000188:drug therapy*; D004338:Drug Combinations; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy*; D007190:Indapamide / Q000627:therapeutic use*; D008833:Microcirculation / Q000187:drug effects; D020913:Perindopril / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D002316:Cardiotonic Agents; D004338:Drug Combinations; C494243:indapamide, perindopril drug combination; D007190:Indapamide; D020913:Perindopril